MA49368A - Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires - Google Patents

Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires

Info

Publication number
MA49368A
MA49368A MA049368A MA49368A MA49368A MA 49368 A MA49368 A MA 49368A MA 049368 A MA049368 A MA 049368A MA 49368 A MA49368 A MA 49368A MA 49368 A MA49368 A MA 49368A
Authority
MA
Morocco
Prior art keywords
imidazopyrimidines
diazabicyclic
substitute
respiratory tract
tract diseases
Prior art date
Application number
MA049368A
Other languages
English (en)
French (fr)
Inventor
Udo Albus
Moritz Beck-Broichsitter
Karl Collins
Martina Delbeck
Doris Gehring
Michael Hahn
Niels Lindner
Klemens Lustig
Thomas Müller
Janine Nicolai
Björn Rosenstein
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA49368A publication Critical patent/MA49368A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049368A 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires MA49368A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17176046 2017-06-14
EP17193252 2017-09-26

Publications (1)

Publication Number Publication Date
MA49368A true MA49368A (fr) 2021-04-14

Family

ID=62492660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049368A MA49368A (fr) 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires

Country Status (33)

Country Link
US (2) US11098063B2 (pt-PT)
EP (1) EP3638675B1 (pt-PT)
JP (2) JP6896113B2 (pt-PT)
KR (1) KR102364134B1 (pt-PT)
CN (4) CN115583959B (pt-PT)
AR (1) AR112099A1 (pt-PT)
AU (1) AU2018283331B2 (pt-PT)
BR (1) BR112019026450A2 (pt-PT)
CA (1) CA3066942A1 (pt-PT)
CL (1) CL2019003650A1 (pt-PT)
CO (1) CO2019014047A2 (pt-PT)
CR (1) CR20190563A (pt-PT)
CU (1) CU24603B1 (pt-PT)
DO (1) DOP2019000308A (pt-PT)
EA (1) EA202090043A1 (pt-PT)
EC (1) ECSP19088492A (pt-PT)
GE (1) GEP20227366B (pt-PT)
HR (1) HRP20240678T1 (pt-PT)
HU (1) HUE066512T2 (pt-PT)
IL (1) IL271117B (pt-PT)
JO (1) JOP20190284A1 (pt-PT)
MA (1) MA49368A (pt-PT)
MX (2) MX2019014983A (pt-PT)
NI (1) NI201900126A (pt-PT)
PE (1) PE20200016A1 (pt-PT)
PH (1) PH12019502828A1 (pt-PT)
PL (1) PL3638675T3 (pt-PT)
RS (1) RS65543B1 (pt-PT)
SG (1) SG11201911508XA (pt-PT)
TW (1) TWI801388B (pt-PT)
UA (1) UA125186C2 (pt-PT)
UY (1) UY37773A (pt-PT)
WO (1) WO2018228907A1 (pt-PT)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017097792A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) * 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
TW202108135A (zh) 2019-05-09 2021-03-01 德商拜耳廠股份有限公司 治療睡眠呼吸中止症之α2-腎上腺素受體亞型C (α-2C)拮抗劑與TASK1/3通道阻斷劑之組合
US20220218700A1 (en) * 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
JOP20220102A1 (ar) 2019-11-06 2023-01-30 Bayer Ag مثبطات المُسْتقبلة الأدرينِية adrac2
JP2023532658A (ja) 2020-07-06 2023-07-31 バイエル・アクチエンゲゼルシヤフト 睡眠時無呼吸の治療のためのアルファ２－アドレナリン受容体サブタイプｃ（アルファ－２ｃ）拮抗薬とｔａｓｋ１／３チャネル遮断薬の組合せ
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds
KR20240124994A (ko) 2021-12-22 2024-08-19 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 p2x3 수용체 길항제의 조합물
WO2023118102A1 (en) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea
AU2022422284A1 (en) 2021-12-22 2024-07-04 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
WO2023131638A1 (en) 2022-01-07 2023-07-13 Bayer Aktiengesellschaft 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea
WO2023131640A1 (en) 2022-01-07 2023-07-13 Bayer Aktiengesellschaft α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
WO2002002557A2 (en) 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
US7855194B2 (en) * 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
WO2007124849A2 (en) * 2006-04-27 2007-11-08 Sanofi-Aventis Deutschland Gmbh Inhibitors of the task-1 and task-3 ion channel
EP2049110B1 (en) * 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
CA2724842A1 (en) 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
RU2576662C2 (ru) 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
US20140221354A1 (en) 2011-03-31 2014-08-07 Emblem Technology Transfer Gmbh IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
WO2013037736A1 (en) 2011-09-12 2013-03-21 Sanofi Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
DK2755973T3 (en) 2011-09-16 2016-01-25 Sanofi Sa SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLE [4,3-C] PYRIDINES, THEIR USE AS MEDICINES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
BR112014006180A2 (pt) * 2011-09-16 2017-04-11 Sanofi Sa 4, 5, 6, 7-tetraidro-1h-pirazol [4, 3-c] piridinas substituídas, seu uso como medicamento e preparações farmacêuticas que compreendem as mesmas
CA2860933C (en) 2012-02-03 2020-01-14 Sanofi Fused pyrroledicarboxamides and their use as pharmaceuticals
WO2014187922A1 (en) * 2013-05-24 2014-11-27 Iomet Pharma Ltd. Slc2a transporter inhibitors
UA118582C2 (uk) 2014-03-26 2019-02-11 Ф. Хоффманн-Ля Рош Аг Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa)
JP2018012645A (ja) * 2014-11-26 2018-01-25 持田製薬株式会社 新規ジアザビシクロ誘導体
TWI585785B (zh) 2014-11-26 2017-06-01 Murata Manufacturing Co Electronic parts manufacturing methods, electronic components and electronic devices
WO2016085784A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
US9994570B2 (en) * 2014-11-26 2018-06-12 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
JP2018016544A (ja) 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ［２．２．２］オクタン誘導体
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
EP3386993A1 (de) 2015-12-10 2018-10-17 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
WO2017097792A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190284A1 (ar) * 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
TW202108135A (zh) 2019-05-09 2021-03-01 德商拜耳廠股份有限公司 治療睡眠呼吸中止症之α2-腎上腺素受體亞型C (α-2C)拮抗劑與TASK1/3通道阻斷劑之組合
US20220218700A1 (en) 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea

Also Published As

Publication number Publication date
RS65543B1 (sr) 2024-06-28
US20200109155A1 (en) 2020-04-09
MX2019014983A (es) 2020-02-24
CN110719911B (zh) 2022-10-21
CN115583959A (zh) 2023-01-10
HUE066512T2 (hu) 2024-08-28
DOP2019000308A (es) 2020-01-31
HRP20240678T1 (hr) 2024-08-16
BR112019026450A2 (pt) 2020-07-14
EP3638675B1 (de) 2024-04-17
EP3638675A1 (de) 2020-04-22
EP3638675C0 (de) 2024-04-17
IL271117A (en) 2020-01-30
AR112099A1 (es) 2019-09-18
AU2018283331B2 (en) 2022-08-04
NI201900126A (es) 2020-04-02
CN115554299A (zh) 2023-01-03
TW201919638A (zh) 2019-06-01
CO2019014047A2 (es) 2020-01-17
CN115583959B (zh) 2024-04-26
UA125186C2 (uk) 2022-01-26
MX2022012716A (es) 2022-11-07
CU24603B1 (es) 2022-06-06
ECSP19088492A (es) 2019-12-27
CN115554300A (zh) 2023-01-03
AU2018283331A1 (en) 2019-12-19
US20220017540A1 (en) 2022-01-20
KR20200014915A (ko) 2020-02-11
JP6896113B2 (ja) 2021-06-30
IL271117B (en) 2022-03-01
CA3066942A1 (en) 2018-12-20
CN110719911A (zh) 2020-01-21
UY37773A (es) 2019-01-02
PH12019502828A1 (en) 2020-10-26
PE20200016A1 (es) 2020-01-06
CR20190563A (es) 2020-04-22
JP2020523388A (ja) 2020-08-06
CL2019003650A1 (es) 2020-07-10
JOP20190284A1 (ar) 2019-12-11
PL3638675T3 (pl) 2024-07-01
SG11201911508XA (en) 2020-01-30
JP2021127346A (ja) 2021-09-02
TWI801388B (zh) 2023-05-11
EA202090043A1 (ru) 2020-04-02
GEP20227366B (en) 2022-03-25
WO2018228907A1 (de) 2018-12-20
CU20190101A7 (es) 2020-10-20
KR102364134B1 (ko) 2022-02-18
US11098063B2 (en) 2021-08-24

Similar Documents

Publication Publication Date Title
MA49368A (fr) Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires
FR22C1011I1 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
HUE049237T2 (hu) Készítmények a bõr sérülései, rendellenességei és betegségei kezelési eljárásaiban történõ alkalmazásra
MA44126A (fr) Méthodes de traitement de maladies et troubles pulmonaires
EP2990017A4 (en) PORTABLE DEVICE FOR TREATING MENIERE DISEASE AND SIMILAR SYMPTOMS
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
MA39950A (fr) Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie
HK1254461A1 (zh) 經修飾的細胞毒素及其治療用途
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
SI3890767T1 (sl) Inhalabilni sestavki za uporabo v zdravljenju pljučnih bolezni
PT3177599T (pt) Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória
IL242694B (en) A subpopulation of monocytes of human origin for the treatment of eye diseases
GB202306894D0 (en) Therapeutic and prohylactic use of microoganisms
IL260987A (en) Treatment and diagnosis of inflammatory disorders
GB201813312D0 (en) Compounds and their therapeutic use
HK1251021A1 (zh) 診斷和治療mers相關腎病
FR3030280B1 (fr) Composition filmogene et son utilisation pour le traitement des affections bucco-linguales
FR3036620B1 (fr) Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires
FR3016881B1 (fr) Traitement des degenerescences et des lesions photo-induites de la retine
MA40969A (fr) Peptide homodimérique pour le traitement du diabète et des maladies liées
IL247732A0 (en) Perinase inhibitory peptides and their use in the treatment of clinical pathologies
MA42467A (fr) Application de la protéine de moule à action adhésive pour le traitement et la prévention de maladies associées à la mélanine
CN302579910S (zh) 红外偏振光治疗仪